PMID- 36281590
OWN - NLM
STAT- MEDLINE
DCOM- 20221026
LR  - 20221026
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 49
IP  - 10
DP  - 2022 Oct
TI  - [The Evolution of the Treatment of Chronic Myelogenous Leukemia].
PG  - 1035-1039
AB  - Chronic myelogenous leukemia(CML)is a myeloproliferative neoplasm caused by a 
      reciprocal translocation (t 9 ; 22) (q34 ; q11). The finding that the 
      constitutive tyrosine kinase activity of the BCR-ABL1 fusion protein, which is 
      produced by fusing the ABL1 and BCR genes, is involved in the pathogenesis of CML 
      has led to the development of drugs targeting the BCR-ABL1 fusion protein. 
      Imatinib, a first-generation tyrosine kinase inhibitor(TKI), was introduced in 
      2001 as a treatment for CML, dramatically changing CML therapy. With the advent 
      of imatinib, disease progression is largely prevented and the prognosis of CML 
      patients is markedly improved, allowing a substantial proportion of patients to 
      remain in the chronic phase for an extended period of time. In the TKI-era, it is 
      no longer the primary disease that defines the long-term prognosis of CML 
      patients, but rather comorbidities other than CML and adverse events(AEs), 
      including cardiovascular events, and management to avoid AEs associated with 
      long-term TKI use has become increasingly important. In recent years, 
      treatment-free remission(TFR)is becoming a new therapeutic goal, as many reports 
      have shown that some patients who have achieved deep molecular response with TKIs 
      can maintain long-term TFR without relapsing after TKI discontinuation.
FAU - Onodera, Koichi
AU  - Onodera K
AD  - Dept. of Hematology, Tohoku University Hospital.
FAU - Fukuhara, Noriko
AU  - Fukuhara N
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - Imatinib Mesylate/therapeutic use
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/genetics
MH  - Fusion Proteins, bcr-abl/genetics/therapeutic use
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Prognosis
EDAT- 2022/10/26 06:00
MHDA- 2022/10/27 06:00
CRDT- 2022/10/25 03:33
PHST- 2022/10/25 03:33 [entrez]
PHST- 2022/10/26 06:00 [pubmed]
PHST- 2022/10/27 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2022 Oct;49(10):1035-1039.